122 related articles for article (PubMed ID: 23424195)
1. WISP3-IGF1 interaction regulates chondrocyte hypertrophy.
Repudi SR; Patra M; Sen M
J Cell Sci; 2013 Apr; 126(Pt 7):1650-8. PubMed ID: 23424195
[TBL] [Abstract][Full Text] [Related]
2. WISP3-dependent regulation of type II collagen and aggrecan production in chondrocytes.
Sen M; Cheng YH; Goldring MB; Lotz MK; Carson DA
Arthritis Rheum; 2004 Feb; 50(2):488-97. PubMed ID: 14872491
[TBL] [Abstract][Full Text] [Related]
3. Mutant WISP3 triggers the phenotype shift of articular chondrocytes by promoting sensitivity to IGF-1 hypothesis of spondyloepiphyseal dysplasia tarda with progressive arthropathy (SEDT-PA).
Yang Y; Liao E
Med Hypotheses; 2007; 68(6):1406-10. PubMed ID: 17363178
[TBL] [Abstract][Full Text] [Related]
4. WISP3 suppresses insulin-like growth factor signaling in human chondrocytes.
Cui RR; Huang J; Yi L; Xie H; Zhou HD; Yuan LQ; Wang M; Peng YQ; Luo XH; Liao EY
Mol Cell Endocrinol; 2007 Dec; 279(1-2):1-8. PubMed ID: 17942216
[TBL] [Abstract][Full Text] [Related]
5. Potential role of WISP3 (CCN6) in regulating the accumulation of reactive oxygen species.
Miller DS; Sen M
Biochem Biophys Res Commun; 2007 Mar; 355(1):156-61. PubMed ID: 17286957
[TBL] [Abstract][Full Text] [Related]
6. IGF1 regulates RUNX1 expression via IRS1/2: Implications for antler chondrocyte differentiation.
Yang ZQ; Zhang HL; Duan CC; Geng S; Wang K; Yu HF; Yue ZP; Guo B
Cell Cycle; 2017 Mar; 16(6):522-532. PubMed ID: 28055425
[TBL] [Abstract][Full Text] [Related]
7. CCN6 regulates mitochondrial function.
Patra M; Mahata SK; Padhan DK; Sen M
J Cell Sci; 2016 Jul; 129(14):2841-51. PubMed ID: 27252383
[TBL] [Abstract][Full Text] [Related]
8. The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling.
Nakamura Y; Weidinger G; Liang JO; Aquilina-Beck A; Tamai K; Moon RT; Warman ML
J Clin Invest; 2007 Oct; 117(10):3075-86. PubMed ID: 17823661
[TBL] [Abstract][Full Text] [Related]
9. Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy.
Wang J; Zhou J; Bondy CA
FASEB J; 1999 Nov; 13(14):1985-90. PubMed ID: 10544181
[TBL] [Abstract][Full Text] [Related]
10. Silencing of WISP3 suppresses gastric cancer cell proliferation and metastasis and inhibits Wnt/β-catenin signaling.
Fang F; Zhao WY; Li RK; Yang XM; Li J; Ao JP; Jiang SH; Kong FZ; Tu L; Zhuang C; Qin WX; He P; Zhang WM; Cao H; Zhang ZG
Int J Clin Exp Pathol; 2014; 7(10):6447-61. PubMed ID: 25400723
[TBL] [Abstract][Full Text] [Related]
11. Canonical Wnt signaling skews TGF-β signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8.
van den Bosch MH; Blom AB; van Lent PL; van Beuningen HM; Blaney Davidson EN; van der Kraan PM; van den Berg WB
Cell Signal; 2014 May; 26(5):951-8. PubMed ID: 24463008
[TBL] [Abstract][Full Text] [Related]
12. Cellular and molecular responses in progressive pseudorheumatoid dysplasia articular cartilage associated with compound heterozygous WISP3 gene mutation.
Zhou HD; Bu YH; Peng YQ; Xie H; Wang M; Yuan LQ; Jiang Y; Li D; Wei QY; He YL; Xiao T; Ni JD; Liao EY
J Mol Med (Berl); 2007 Sep; 85(9):985-96. PubMed ID: 17483925
[TBL] [Abstract][Full Text] [Related]
13. WISP3, the gene responsible for the human skeletal disease progressive pseudorheumatoid dysplasia, is not essential for skeletal function in mice.
Kutz WE; Gong Y; Warman ML
Mol Cell Biol; 2005 Jan; 25(1):414-21. PubMed ID: 15601861
[TBL] [Abstract][Full Text] [Related]
14. WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer.
Kleer CG; Zhang Y; Pan Q; Merajver SD
Neoplasia; 2004; 6(2):179-85. PubMed ID: 15140407
[TBL] [Abstract][Full Text] [Related]
15. CCN6 regulates mitochondrial respiratory complex assembly and activity.
Padhan DK; Sengupta A; Patra M; Ganguly A; Mahata SK; Sen M
FASEB J; 2020 Sep; 34(9):12163-12176. PubMed ID: 32686858
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals.
Garcia Segarra N; Mittaz L; Campos-Xavier AB; Bartels CF; Tuysuz B; Alanay Y; Cimaz R; Cormier-Daire V; Di Rocco M; Duba HC; Elcioglu NH; Forzano F; Hospach T; Kilic E; Kuemmerle-Deschner JB; Mortier G; Mrusek S; Nampoothiri S; Obersztyn E; Pauli RM; Selicorni A; Tenconi R; Unger S; Utine GE; Wright M; Zabel B; Warman ML; Superti-Furga A; Bonafé L
Am J Med Genet C Semin Med Genet; 2012 Aug; 160C(3):217-29. PubMed ID: 22791401
[TBL] [Abstract][Full Text] [Related]
17. WISP3 prevents fibroblast-myofibroblast transdifferentiation in NRK-49F cells.
Yi Y; Ma J; Jianrao L; Wang H; Zhao Y
Biomed Pharmacother; 2018 Mar; 99():306-312. PubMed ID: 29353205
[TBL] [Abstract][Full Text] [Related]
18. Identification of a mutation in the WISP3 gene in three unrelated families with progressive pseudorheumatoid dysplasia.
Yu Y; Hu M; Xing X; Li F; Song Y; Luo Y; Ma H
Mol Med Rep; 2015 Jul; 12(1):419-25. PubMed ID: 25738435
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia.
Hurvitz JR; Suwairi WM; Van Hul W; El-Shanti H; Superti-Furga A; Roudier J; Holderbaum D; Pauli RM; Herd JK; Van Hul EV; Rezai-Delui H; Legius E; Le Merrer M; Al-Alami J; Bahabri SA; Warman ML
Nat Genet; 1999 Sep; 23(1):94-8. PubMed ID: 10471507
[TBL] [Abstract][Full Text] [Related]
20. Progressive pseudorheumatoid dysplasia: a rare childhood disease.
Torreggiani S; Torcoletti M; Campos-Xavier B; Baldo F; Agostoni C; Superti-Furga A; Filocamo G
Rheumatol Int; 2019 Mar; 39(3):441-452. PubMed ID: 30327864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
